Presentation of New Data on Inivata’s Industry-Leading Liquid Biopsy Platform at AACR 2018 Annual Meeting

2018, News

Oral presentations and posters to feature Inivata’s InVision® liquid biopsy platform and its application

Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, announces that cutting-edge data on the performance of its liquid biopsy platform, InVision®, will be showcased in two oral presentations and two posters at the American Association for Cancer Research (AACR) Annual Meeting 14-18 April in Chicago. The details are as follows:

Presentation: Longitudinal circulating-tumor DNA profiling of EGFR-mutated non-small cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors
Date and time: April 15, 2018, 3:20PM – 3:35PM
Location: Room S105 – McCormick Place South (Level 1)
For the list of authors, click here. Webcast Available May 9

Presentation: Analytical validation of InVisionFirst™, a liquid biopsy assay for high-sensitivity broad molecular profiling of circulating tumor DNA using plasma samples of cancer patients
Date and time: April 15, 2018, 3:50PM – 4:05PM
Location: Room S105 – McCormick Place South (Level 1)
For the list of authors, click here. Webcast Available May 9

Poster: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas
Date and time: April 16, 2018, 8:00AM – 12:00PM
Location: Section 36
For the list of authors, click here.

Poster: Feasibility of an amplicon-based liquid biopsy for ALK and ROS1 fusions in advanced non-small cell lung cancer (NSCLC) patients
Date and time: April 17, 2018, 1:00 PM – 5:00 PM
Location: Section 27
For the list of authors, click here.

 

About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high caliber publications. Its lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

 

Media Contacts

Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson (UK)
Catherine London (US)

inivata@consilium-comms.com +44 (0)20 3709 5700

Inivata
Karen Chandler-Smith

karen.chandler-smith@inivata.com +44 (0)7900 430235

 

Our Technology

Our Solutions

Latest News